فيروس إبشتاين-بار والتصلب المتعدد: ما الذي تغيّره الدراسة الجديدة حول الانتكاسات

Almost every adult carries the Epstein-Barr virus, and almost nobody develops multiple sclerosis. That gap is the whole difficulty of a question people ask their doctor constantly: if EBV is involved in multiple sclerosis, can a blood test tell me anything? A study published in Nature Medicine on September 16, 2026 by Mass General Brigham researchers moves the question forward. Analysing blood from 114 people with multiple sclerosis, the team detected a surge of EBV activity inside immune cells up to three months before a relapse. This article explains what was measured, why that is different from a standard EBV serology, which laboratory analyses actually surround a multiple sclerosis workup, and what an abnormal result does and does not mean.

What the September 2026 study actually measured

Researchers used blood samples from the CLIMB cohort at Brigham and Women’s Hospital, a study that has followed people with multiple sclerosis for decades. They compared samples drawn up to 90 days before a relapse with samples from the same people during remission, plus 21 healthy participants.

Using single-cell RNA sequencing, they looked at hundreds of thousands of individual immune cells rather than at the blood as a whole. B cells stood out. These are the immune cells where EBV lies dormant for life, and before a relapse they switched on genes linked to antiviral response, inflammation and EBV activity. The team also found more ABC-like B cells, a subset associated with viral infection and autoimmune disease.

The key observation is a sequence: EBV proteins appeared to switch on multiple sclerosis risk genes inside immune cells before a relapse, but not during remission and not in healthy participants. That timeline is what suggests a triggering role rather than a coincidence.

Why this is not the EBV test your laboratory runs

A standard EBV serology measures antibodies in serum. It answers one question well: have you met this virus, recently or in the past. The September study measured something else entirely, namely gene activity inside sorted immune cells, using research techniques that no city laboratory performs.

The distinction matters because the two tests answer different questions. Antibody titres tell you about exposure history. Single-cell sequencing told researchers what those cells were doing in the weeks before an attack. A blood biomarker of EBV activity, usable in routine care, does not exist yet. The authors say so explicitly: the findings need validation in larger prospective studies before anything reaches a laboratory request form.

The analyses that actually surround a multiple sclerosis workup

Multiple sclerosis is not diagnosed on a blood test. According to the National Institute of Neurological Disorders and Stroke, diagnosis rests on symptoms, a neurological examination and MRI, sometimes completed by a lumbar puncture. Blood analyses are there to rule other things out and, increasingly, to monitor.

Our library covers in plain language the GFAP blood marker in multiple sclerosis monitoring. A separate page explains the principle of a serology panel، وتصف مقالة أخرى the role of lymphocytes in a blood count.

What EBV serology can and cannot tell you

Roughly nine adults in ten carry antibodies showing a current or past EBV infection, according to the Centers for Disease Control and Prevention. A positive EBNA-1 IgG in an adult is therefore the expected result, not an alarm. It means the virus entered your body, usually years ago, and now sits dormant in your B cells, as it does in most of the population.

The reverse is also informative in a narrow way. People who have never been infected with EBV have a lower risk of multiple sclerosis than those who have. But the overwhelming majority of infected people never develop the disease, which is why no health authority recommends EBV serology as a screening test for multiple sclerosis. The Inserm dossier on the subject still describes the infectious pathway as a hypothesis rather than a demonstrated cause.

Practically: a positive EBV serology does not announce multiple sclerosis, and a high antibody titre is not a relapse warning. We explained the same limits in a different setting when we reviewed EBV reactivation after a severe COVID infection.

When a result deserves a medical opinion

A laboratory number rarely speaks alone. A few situations justify a conversation with a physician rather than a search engine:

• New neurological symptoms lasting more than 24 hours: vision loss in one eye, numbness spreading over days, unexplained loss of balance.
• Extreme fatigue with fever, sore throat and swollen neck nodes in a teenager or young adult, which points toward mononucleosis rather than anything neurological.
• An EBV serology requested without symptoms, which is rarely informative on its own.
• A known multiple sclerosis diagnosis with symptoms that worsen over several days, which needs to be assessed as a possible relapse.
• Any abnormal result that arrives without context, which your physician can place against your history.

Our overview describes the symptoms and diagnosis of multiple sclerosis in detail, and a companion page explains what to do about abnormal blood test results.

أحدث التطورات العلمية

Research published in the past three years puts the September study in context. According to PubMed, the picture is genuinely mixed, and that mix is the honest answer.

An Austrian team followed 324 people with multiple sclerosis and 324 matched controls from the moment they first became infected with EBV. Antibody levels against the EBNA-1 protein were already higher in those who would go on to be diagnosed, on average more than five years before diagnosis. What this means for you: at the scale of a population, antibody levels carry a signal. At the scale of one person, they do not tell you whether you will be affected.

A Buffalo team pushed the same idea in the other direction. Following 187 people for five and a half years, they confirmed that antibody titres are higher in multiple sclerosis, but found no link between baseline titres and later disability, MRI lesions or nerve damage markers. What this means for you: EBV antibody levels are not a way to follow your own disease, and a rising titre is not a reason to expect a relapse.

Two further lines of work explain why researchers keep looking. A Danish group measured viral microRNAs, small fragments produced by EBV, directly in whole blood, and found higher levels in patients classified as having active disease. A Copenhagen team tested antibody indices combining serum and spinal fluid, which slightly improved diagnostic sensitivity alongside existing tests. What this means for you: both remain research tools, and neither is offered as a routine analysis today.

مسرد المصطلحات

الأسئلة الشائعة

Does a positive EBV test mean I will develop multiple sclerosis?

No. About nine adults in ten have antibodies showing a past EBV infection, and the overwhelming majority never develop multiple sclerosis. A positive serology in an adult is the expected finding. Having never been infected is associated with a lower risk, but that does not make a positive result predictive at the level of one person.

Should I ask for an EBV serology if a relative has multiple sclerosis?

There is no medical reason to. No guideline recommends EBV serology to assess multiple sclerosis risk, because the result would almost certainly be positive and would change nothing in your care. If you are worried about a family history, discuss the symptoms that would matter with your physician instead.

Can a blood test predict a multiple sclerosis relapse today?

Not in routine care. The September 2026 study found EBV activity signals up to three months before relapse, but using research techniques on sorted immune cells, not a test you can order. Neurofilament light chain and GFAP are used in specialist settings to monitor activity, and even they are interpreted alongside MRI rather than on their own.

I had mononucleosis as a teenager. Am I at higher risk?

Infection with EBV in adolescence or adulthood is associated with a modestly higher risk than childhood infection, according to the National Institute of Neurological Disorders and Stroke. The word to hold onto is modest. Most people who had mononucleosis never develop multiple sclerosis, and there is nothing to monitor in the absence of symptoms.

Does this study change my treatment?

Not today. Current disease-modifying therapies work by regulating the immune system broadly. The researchers suggest that targeting EBV or the specific B cells involved could eventually allow more precise approaches, but that is a research direction, not an available option. Treatment decisions remain with your neurology team.

Why do B cells keep coming up in multiple sclerosis research?

Because they sit at the intersection of the two threads. B cells are where EBV lies dormant, and several of the most effective multiple sclerosis treatments work by depleting them. The September study offers a possible explanation for why those two facts are connected.

مصادر

• National Institute of Neurological Disorders and Stroke — Multiple Sclerosis (MS), reviewed December 2025 — ninds.nih.gov
• Centers for Disease Control and Prevention — About Epstein-Barr Virus (EBV), May 2024 — cdc.gov
• Mass General Brigham — Researchers discover how Epstein-Barr virus triggers multiple sclerosis attacks, September 16, 2026 — massgeneralbrigham.org
• Inserm — Sclérose en plaques (SEP), dossier d’information — inserm.fr
• King DA, et al. — EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse — Nature Medicine, 2026 — doi.org/10.1038/s41591-026-04665-3
• Vietzen H, et al. — Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1-specific antibody titers — Nature Communications, 2025 (PubMed) — doi.org/10.1038/s41467-025-61751-9
• Semy M, et al. — Evaluating the role of anti-EBV antibodies as biomarkers for the evolution of multiple sclerosis: a longitudinal study — Multiple Sclerosis and Related Disorders, 2025 (PubMed) — doi.org/10.1016/j.msard.2025.106695
• Hvalkof VH, et al. — Profiling of Epstein-Barr Virus microRNAs in Whole Blood and Exosomes in Multiple Sclerosis — Immunological Investigations, 2025 (PubMed) — doi.org/10.1080/08820139.2025.2559799
• Ali R, et al. — Epstein-Barr nuclear antigen 1 antibody-based indices are increased in patients with multiple sclerosis — Multiple Sclerosis and Related Disorders, 2024 (PubMed) — doi.org/10.1016/j.msard.2024.106173

للمزيد من القراءة

• MS blood test: what GFAP adds to multiple sclerosis monitoring
• Multiple sclerosis: symptoms, causes, types and diagnosis
• EBV reactivation after COVID: what your blood test results mean
• شرح اختبار الأجسام المضادة: فهم لوحة الأمراض المعدية
• Lymphocytes explained: understanding this blood marker
• Abnormal blood test results: what to do next

افهم نتائج مختبرك باستخدام AI DiagMe

An EBV serology rarely means what people fear it means. VCA IgM, VCA IgG and EBNA-1 only make sense together, and against your own history and symptoms. AI DiagMe reads your laboratory report and explains, in ordinary language, what each value measures and which combinations deserve a medical opinion. It helps you understand your results and prepare your questions; it does not diagnose and does not replace your physician.

احصل على تفسير نتائجك في دقائق